STOCK TITAN

Erasca (ERAS) SEC Filings, Jun-Jul 2026

ERAS NASDAQ

Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.

Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.

Rhea-AI Summary

Erasca, Inc. is conducting a primary offering of $500,000,000 of common stock under its shelf registration, with underwriters holding a 30‑day option to buy up to an additional $75,000,000. Its common stock trades on the Nasdaq Global Select Market under the symbol “ERAS,” last reported at $18.53 on July 10, 2026.

Shares outstanding were 310,806,888 as of March 31, 2026; this is a baseline figure, not the amount being offered, and excludes any shares from this transaction or up to $200 million available under an at‑the‑market Sales Agreement. The company is a clinical‑stage precision oncology developer targeting RAS/MAPK‑driven cancers, with clinical programs ERAS‑0015 (pan‑RAS molecular glue) and ERAS‑4001 (pan‑KRAS inhibitor) plus discovery program ERAS‑12. Net proceeds, together with existing cash, will fund research and development, working capital, general corporate purposes and potential in‑licensing or acquisitions.

Erasca highlights that new investors will experience immediate and substantial dilution relative to net tangible book value of $393.5 million, or $1.27 per share, as of March 31, 2026. Updated preliminary AURORAS‑1 Phase 1 data for ERAS‑0015 in 72 patients with RAS‑mutant NSCLC and PDAC treated at 16–32 mg showed treatment‑related rash in 72% and diarrhea in 32% of patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.94%
Tags
prospectus
-
Rhea-AI Summary

Erasca, Inc. reported updated preliminary Phase 1 data from the ongoing AURORAS-1 trial of ERAS-0015, described as a potentially best-in-class, pan-RAS molecular glue in patients with RAS-mutant solid tumors. The update adds patients and longer follow-up to earlier April 2026 results.

Among 72 patients with RAS-mutant NSCLC and pancreatic ductal adenocarcinoma treated at the protocol-amended dose, treatment-related adverse events were mainly low grade. Rash occurred in 52 patients (72%), diarrhea in 23 (32%), stomatitis in 14 (19%), and nausea in 10 (14%). Events led to dose interruptions in 9 patients (13%) and dose reductions in 6 (8%), with no treatment-related adverse events causing discontinuation.

The company highlights encouraging monotherapy responses in second-line or later KRAS G12X pancreatic ductal adenocarcinoma, promising combination potential with panitumumab in metastatic colorectal cancer, and plans to accelerate potentially registration-enabling studies. Extensive risk disclosures emphasize that these are interim, forward-looking assessments subject to delay, changing data, regulatory feedback, safety and efficacy outcomes, intellectual property disputes, and funding constraints.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.94%
Tags
current report
-
Rhea-AI Summary

Erasca, Inc., a Delaware-based clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway–driven cancers, has filed an automatic shelf registration as a well-known seasoned issuer. The shelf allows Erasca to offer, from time to time after effectiveness, various securities, including common stock, preferred stock, debt securities, warrants and units, with specific terms and amounts to be set in future prospectus supplements. Any securities may be sold through underwriters, dealers, agents, directly to investors, or a combination of these methods.

As of March 31, 2026, Erasca’s authorized capital stock consists of 800,000,000 shares of common stock and 80,000,000 shares of preferred stock. Its common stock trades on the Nasdaq Global Select Market under the symbol ERAS, with a last reported price of $18.53 per share on July 10, 2026. The company’s pipeline includes two clinical-stage programs, ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS inhibitor), plus ERAS-12 (an EGFR D2/D3 biparatopic antibody) in discovery. The filing also describes existing registration rights that permit certain holders to demand registrations for offerings of at least $20.0 million on Form S-1 and $5.0 million on Form S-3, with those rights expiring in August 2026, as well as anti-takeover and forum-selection provisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.94%
Tags
other
Rhea-AI Summary

Erasca, Inc. held its annual meeting of stockholders on June 26, 2026. As of the April 27, 2026 record date, 310,965,971 shares were entitled to vote, and 266,073,906 shares were represented in person or by proxy, establishing a strong quorum.

Stockholders elected three Class II directors—Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.—to three-year terms expiring at the 2029 annual meeting. Votes for these nominees ranged from 219,569,944 to 223,863,013, with 25,593,152 to 29,886,221 withheld and 16,617,741 broker non-votes.

Stockholders also ratified the appointment of KPMG LLP as Erasca’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with no broker non-votes recorded for this proposal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
current report
-
Rhea-AI Summary

Erasca, Inc. director Valerie Denise Harding received a stock option grant covering 29,888 shares of Common Stock. The options have an exercise price of $16.01 per share and expire on June 26, 2036.

All 29,888 options vest on June 26, 2027, provided she remains in continuous service with the company through that date. Following this grant, she holds 29,888 derivative securities directly, reflecting a routine, compensation-related award rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
insider
-
Rhea-AI Summary

Erasca, Inc. director Jean I. Liu received a stock option grant covering 29,888 shares of common stock on June 26, 2026. The option has an exercise price of $16.01 per share and expires on June 26, 2036. According to the filing, Liu now holds options for 29,888 shares following this award. The grant vests 100% on June 26, 2027, subject to her continuous service with the company until that date, and represents equity compensation rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
insider
Rhea-AI Summary

Erasca, Inc. director Pratik S. Multani received a stock option grant covering 29,888 shares of common stock. The option has an exercise price of $16.01 per share and expires on June 26, 2036.

All of these options vest on June 26, 2027, as long as the director continues to serve the company through that date. After this grant, the filing shows 29,888 option shares held directly, with no remaining prior derivative positions listed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
insider
-
Rhea-AI Summary

Erasca, Inc. director Alexander W. Casdin received a grant of stock options covering 29,888 shares of common stock. The options have an exercise price of $16.01 per share, expire on June 26, 2036, and vest 100% on June 26, 2027, contingent on his continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
insider
-
Rhea-AI Summary

Erasca, Inc. director Julie Hambleton reported receiving a stock option grant as part of her compensation. She was awarded options covering 29,888 shares of common stock at an exercise price of $16.01 per share. These options vest 100% on June 26, 2027, provided she continues serving the company through that date, and expire on June 26, 2036. Following this grant, she holds stock options for 29,888 shares directly. This is a compensation-related award rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
insider
Rhea-AI Summary

Erasca, Inc. director James Arthur Bristol received a grant of stock options as part of his compensation. The award covers 29,888 options to buy common stock at an exercise price of $16.01 per share. These options were granted at no cost on the grant date.

The options vest 100% on June 26, 2027, provided he continues serving the company through that date, and they expire on June 26, 2036. After this grant, he holds 29,888 stock options directly, with no open-market share purchases or sales reported in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
insider

FAQ

How many Erasca (ERAS) SEC filings are available on StockTitan?

StockTitan tracks 88 SEC filings for Erasca (ERAS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Erasca (ERAS)?

The most recent SEC filing for Erasca (ERAS) was filed on November 20, 2026.